✦ LIBER ✦

Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer

✍ Scribed by Shailendra Verma; Angela Rocchi

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Single-agent gemcitabine as second- and

✍ T. Brodowicz; W.J. Kostler; R. Möslinger; S. Tomek; I. Vaclavik; V. Herscovici; 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 131 KB

Single-agent gemcitabine as second- and

✍ W.J. Köstler; T. Brodowicz; R. Möslinger; S. Tomek; I. Vaclavik; V. Herscovici; 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 170 KB

PCN14 COST-EFFECTIVENESS OFTAXANES AS SE

✍ AA Kawatkar; JW Hay 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 48 KB

Treatment Choices for Second-Line Chemot

✍ Christoph C. Zielinski 📂 Article 📅 2003 🏛 Springer US 🌐 English ⚖ 55 KB

PCN74 Economic Evaluation of Everolimus

✍ Nevarez-Sida, A.; Fuentes-Alburo, A. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Cabazitaxel In Second Line (2l) Treatmen

✍ Joulain, F.; Zavisic, S.; Mehta, J. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB